PPM. These charges averaged about $14 PPM (P = 0.069) and $9 PPM (P = 0.231) lower than those of risperidone and olanzapine, respectively, a savings of 2%-3% based on a $526 PPM mean charge. Differences in nonantipsychotic mental health care charges PPM among bipolar patients treated with risperidone, olanzapine, or quetiapine were largely explained by differing patient and treatment characteristics rather than the antipsychotic used. After dosage levels were standardized, however, olanzapine was associated with significantly higher drug acquisition costs than those of risperidone and quetiapine (57% and 49% respectively; P < 0.01). Although the difference in drug charges between risperidone and quetiapine was not statistically significant, quetiapine was associated with lower PPM resource utilization. CON-CLUSION: Quetiapine appears to be associated with modestly lower non-antipsychotic mental health resource use compared to risperidone and olanzapine for treatment of bipolar disorder.
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PATTERNS OF TREATMENT AMONG BIPOLAR DISORDER PATIENTS TREATED WITH ANTIDEPRESSANTS
Birnbaum HG 1 , Dial E 1 , Oster EF 1 , Greenberg PE 1 , Shi L 2 1 Analysis Group/Economics, Boston, MA, USA; 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVE: This study compared treatment patterns for bipolar disorder (BP) patients (recognized and unrecognized) to those of major depression disorder (MDD) patients without a BP claim (non-BP) during the observational period. METHODS: An employer administrative claims database (covering several managed care health plans from 1998-2001) was used to identify 11,464 patients diagnosed with MDD and initially treated with antidepressants (AD). Of these, unrecognized BP (UBP) patients received their initial BP diagnosis and/or mood stabilizer (MS) prescription after AD initiation, while recognized BP (RBP) patients had these records on/before AD initiation. Induced BP patients were defined as those manifesting mania within six months after starting AD. RESULTS: BP patients accounted for 6.8% of the research sample (3.7% UBP and 3.1% RBP). Induced BP represented 6.6% of all BP patients. RBP patients had a slightly lower rate of induction (6.2%) than UBP patients (6.9%). The use of combination therapies varied in the non-BP, UBP, and RBP patients (11%, 32%, and 43%, respectively) (all pairwise p < 0.01). The use of MS was less frequent among UBP than RBP patients (14% and 34%, respectively) (p < 0.0001). CONCLUSIONS: A substantial number of AD-treated MDD patients could be classified as bipolar (either RBP or UBP), and were at risk for induction of mania. RBP and UBP patients initiated with more combination therapies, as compared to Non-BP patients. MS use increased when BP was recognized. More effort is needed to quickly diagnose and effectively treat BP patients. (RedBook 2002) . Outcome measures included days in acute care, total direct medical costs, and incremental costs. RESULTS: Because of greater tolerability, estimated days in acute care were lowest for ziprasidone (42.4) when compared to olanzapine (42.8), risperidone (43.1), or haloperidol (53.6). Due to lower estimated days in acute care and lower maintenance treatment drug costs, estimated annual total healthcare costs for each drug cohort (n = 1000 patients per cohort) were lowest for those patients initiating treatment with ziprasidone vs. risperidone (+$787,000), olanzapine (+$964,000), or haloperidol (+$4,210,000). Sensitivity analyses to changes in model assumptions for adverse event, adherence, and relapse rates, and healthcare costs were robust to these conclusions. CONCLUSION: Ziprasidone has an adverse event profile distinct from those of other atypical antipsychotics and lower pharmaceutical acquisition costs, which potentially lead to improved outcomes and lower total direct costs.
